Knight Therapeutics, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CA4990531069
CAD
6.05
0.01 (0.17%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

20.47 k

Shareholding (Dec 2023)

FII

0.15%

Held by 1 FIIs

DII

99.85%

Held by 0 DIIs

Promoter

0.00%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

With a fall in PBT of -809.79%, the company declared Very Negative results in Jun 25

  • INTEREST(Q) At CAD 2.37 MM has Grown at 35.19%
  • RAW MATERIAL COST(Y) Grown by 15.29% (YoY)
  • CASH AND EQV(HY) Lowest at CAD 232.7 MM
2

Underperformed the market in the last 1 year

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

CAD 581 Million (Small Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.01

stock-summary
Return on Equity

-0.11%

stock-summary
Price to Book

0.76

Revenue and Profits:
Net Sales:
107 Million
(Quarterly Results - Jun 2025)
Net Profit:
-13 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-6.06%
0%
-6.06%
6 Months
3.95%
0%
3.95%
1 Year
12.87%
0%
12.87%
2 Years
14.8%
0%
14.8%
3 Years
10.81%
0%
10.81%
4 Years
16.12%
0%
16.12%
5 Years
14.58%
0%
14.58%

Knight Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
22.33%
EBIT Growth (5y)
-1.70%
EBIT to Interest (avg)
-1.52
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.11
Sales to Capital Employed (avg)
0.41
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.15%
ROCE (avg)
0.11%
ROE (avg)
1.02%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.75
EV to EBIT
-65.07
EV to EBITDA
13.85
EV to Capital Employed
0.75
EV to Sales
1.52
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-1.16%
ROE (Latest)
-0.11%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2023stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.15%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 21.91% vs -9.08% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -672.73% vs -79.44% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "107.40",
          "val2": "88.10",
          "chgp": "21.91%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "8.50",
          "val2": "6.00",
          "chgp": "41.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "2.40",
          "val2": "1.80",
          "chgp": "33.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-5.70",
          "val2": "-0.90",
          "chgp": "-533.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-12.60",
          "val2": "2.20",
          "chgp": "-672.73%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-34.20%",
          "val2": "-62.90%",
          "chgp": "2.87%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 13.13% vs 11.78% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 125.60% vs 43.81% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "371.30",
          "val2": "328.20",
          "chgp": "13.13%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "60.60",
          "val2": "56.80",
          "chgp": "6.69%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "9.20",
          "val2": "12.50",
          "chgp": "-26.40%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-11.60",
          "val2": "-13.50",
          "chgp": "14.07%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "4.30",
          "val2": "-16.80",
          "chgp": "125.60%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "20.20%",
          "val2": "19.60%",
          "chgp": "0.06%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
107.40
88.10
21.91%
Operating Profit (PBDIT) excl Other Income
8.50
6.00
41.67%
Interest
2.40
1.80
33.33%
Exceptional Items
-5.70
-0.90
-533.33%
Consolidate Net Profit
-12.60
2.20
-672.73%
Operating Profit Margin (Excl OI)
-34.20%
-62.90%
2.87%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 21.91% vs -9.08% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -672.73% vs -79.44% in Mar 2025

Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
371.30
328.20
13.13%
Operating Profit (PBDIT) excl Other Income
60.60
56.80
6.69%
Interest
9.20
12.50
-26.40%
Exceptional Items
-11.60
-13.50
14.07%
Consolidate Net Profit
4.30
-16.80
125.60%
Operating Profit Margin (Excl OI)
20.20%
19.60%
0.06%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 13.13% vs 11.78% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 125.60% vs 43.81% in Dec 2023

stock-summaryCompany CV
About Knight Therapeutics, Inc. stock-summary
stock-summary
Knight Therapeutics, Inc.
Pharmaceuticals & Biotechnology
Knight Therapeutics Inc is a Canada-based specialty pharmaceutical company. The Company is engaged in developing, acquiring, in-licensing, out-licensing, marketing and distributing pharmaceutical products, consumer health products and medical devices. The Company’s products are ILUVIEN Fluocinolone acentonid, Nerlynx Neratinib Tablets, Burinex Bumetanide, Probuphine Buprenorphine implant and Movantik Naloxegol.
Company Coordinates stock-summary
Company Details
3400 De Maisonneuve Blvd W , MONTREAL QC : H3Z 3B8
stock-summary
Tel: 1 514 4844483
stock-summary
Registrar Details